323 related articles for article (PubMed ID: 32755564)
1. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs AC; Larson RC; Marjanovic ND; Gosik K; Castano AP; Porter CBM; Lorrey SJ; Ashenberg O; Jerby L; Hofree M; Smith-Rosario G; Morris R; Gould J; Riley LS; Berger TR; Riesenfeld SJ; Rozenblatt-Rosen O; Choi BD; Regev A; Maus MV
Mol Ther; 2020 Dec; 28(12):2577-2592. PubMed ID: 32755564
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling.
Philipson BI; O'Connor RS; May MJ; June CH; Albelda SM; Milone MC
Sci Signal; 2020 Mar; 13(625):. PubMed ID: 32234960
[TBL] [Abstract][Full Text] [Related]
3. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
4. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
[TBL] [Abstract][Full Text] [Related]
5. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
7. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
8. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
9. Modification of Hinge/Transmembrane and Signal Transduction Domains Improves the Expression and Signaling Threshold of GXMR-CAR Specific to
Dos Santos MH; Machado MP; Kumaresan PR; da Silva TA
Cells; 2022 Oct; 11(21):. PubMed ID: 36359781
[TBL] [Abstract][Full Text] [Related]
10. Designed improvement to T-cell immunotherapy by multidimensional single cell profiling.
Bandey IN; Adolacion JRT; Romain G; Paniagua MM; An X; Saeedi A; Liadi I; You Z; Rajanayake RB; Hwu P; Singh H; Cooper LJ; Varadarajan N
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722906
[TBL] [Abstract][Full Text] [Related]
11. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
12. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
13. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
14. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
15. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
16. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
[TBL] [Abstract][Full Text] [Related]
17. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
[TBL] [Abstract][Full Text] [Related]
18. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
19. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
[TBL] [Abstract][Full Text] [Related]
20. Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.
Meng X; Jing R; Qian L; Zhou C; Sun J
Front Immunol; 2020; 11():1046. PubMed ID: 32636832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
